Innate Pharma (IPHA) — Cash Flow Reinvestment Rate
Latest as of June 2024:
0.09x
Innate Pharma (IPHA) has a Cash Flow Reinvestment Rate of 0.09x as of June 2024, reinvesting $283.00K (capex $283.00K ) from operating cash flow of $3.04 Million. Explore IPHA capex reinvestment rate to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
0.09x
(Capex + Investments) / Operating CF
Total Reinvested
$283.00K
Capex + Investments
Operating Cash Flow
$3.04 Million
USD
Capital Expenditures
$283.00K
USD
Innate Pharma Cash Flow Reinvestment Rate (2006–2019)
Historical reinvestment intensity for Innate Pharma across 4 annual periods. Also explore balance sheet size of Innate Pharma for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Innate Pharma (2006–2019)
Year-by-year capital reinvestment analysis for Innate Pharma. For live market cap and broader valuation context, see Innate Pharma stock valuation.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2019 | 3.65x | $127.52 Million | $34.92 Million | $65.40 Million | ▲ +469.8% |
| 2015 | 0.64x | $133.24 Million | $207.91 Million | $7.40 Million | ▲ +2484.4% |
| 2011 | 0.02x | $322.00K | $12.99 Million | $322.00K | ▼ -98.8% |
| 2006 | 2.09x | $752.00K | $360.00K | $752.00K | — |
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow